Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - edoxaban tosylate [ID662]: committee papers

Table of contents

01 Pre-meeting briefing
02 Evidence Review Group report
03 Evidence Review Group report - factual accuracy check
04 Erratum to the ERG report
05 Additional Erratum to the ERG report
06 Manufacturer submission - Daiichi Sankyo
07 NICE clarification letter
08 Company clarification letter responses
09 Consultee statement - Anticoagulation Europe
10 Consultee statement - British Society for Haemostasis and Thrombosis
11 Consultee statement - Clinical Leaders of Thrombosis (CLOT)
12 Consultee statement - Lifeblood The Thrombosis Charity
13 Consultee statement - United Kingdom Clinical Pharmacy Association (UKCPA)
14 Clinical expert statement - HOWARD
15 Patient expert statement - HUNT
16 Patient expert statement - EATON

This page was last updated: 10 July 2015